Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Slides:

Advertisements

Similar presentations

North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.

Advertisements

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Zontivity™ - vorapaxar

Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

PRODIGY Objective Study Design Primary Composite Endpoint

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

DAPT Mortality and Cancer: Focus on HIRA Database

SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

NOACs for Cancer-Associated Thrombosis:

Oral Anticoagulation and Preventing Stent Thrombosis

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Medical Therapy for Peripheral Artery Disease

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

The following slides highlight a discussion and analysis of presentations in the Late-Breaking Clinical Trials session from the 55th Annual Scientific.

PAD Patients vs Post-ACS Patients:

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Terms of Use. Terms of Use.

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

NOACS: Emerging data in ACS/IHD

Efficacy and Safety of Edoxaban in Patients With AF and HF

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

Understanding PAD.

Dos and Don’ts for High-Risk Elderly Patients With AF

Practical Considerations to Extend Treatment for VTE

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

CV Risk Doesn't End in the Cath Lab

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

CAD and HF Often Coexist

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease Ehrin.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

ESC Guideline on the Management of STEMI Recommendation for DAPT

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Section C: Clinical trial update: Oral antiplatelet therapy

Translating Data From Trial to Practice

Presentation transcript:

Natural History of Atherothrombosis

Finding the Right Risk-Benefit Balance

Outcomes in Patients With Atherosclerotic Vascular Disease

CHARISMA Study Primary Efficacy Results (MI/Stroke/CV Death) by Prespecified Entry Category

Monotherapy Clopidogrel vs Aspirin in Patients at Risk for Ischemic Events (CAPRIE)

REACH Data

Long-Term Dual Antiplatelet Therapy After MI?

TRILOGY ACS Post Hoc Analysis

Why Not Treat Everyone With Long-Term Thienopyridine Therapy?

Central Role of Thrombin as a Mediator of Coagulation and Platelet Thrombosis

PAR-1 Antagonists

TRA (Vorapaxar) Program Evaluation of Efficacy and Safety in Acute and Chronic Atherothrombosis

TRA-CER Trial Vorapaxar in ACS

TRA 2◦P-TIMI 50 Safety and Efficacy at 3 Years

TRA 2◦P-TIMI 50 MI Subgroup at 3 Years

Patients Considered for Long-Term, Higher Potency Antiplatelet Therapy

Addition of Vorapaxar

TRA◦2P-TIMI 50 Peripheral Artery Disease Cohort

DAPT Study Design

PEGASUS-TIMI 54 Trial

Take-home Points and Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)